A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma.

NCT00677105 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma
Neoplasms

Interventions

DRUG: JNJ-26481585

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

[object Object]